Compare General Dynamics Corporation (GD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs TransMedics Group Inc — how do they compare? General Dynamics Corporation trades at $391.37 (market cap $106.03B), while TransMedics Group Inc trades at $86.78 (market cap $3.10B). The key difference: General Dynamics Corporation is far larger — about 34.2× TransMedics Group Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| GD | TMDX | |
|---|---|---|
Market Cap | $106.03B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $395.97 | $150.42 |
52-Week Low | $312.53 | $61.99 |
Enterprise Value | $111.17B | $3.49B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $395.97, up 1.0% on the day, near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats, including Q2 2026 EPS of $4.24 versus $3.96 expected. Revenue growth is robust, with 2025 revenue at $52.55 billion, and the company secured a major $76.6 billion Navy contract in July 2026, boosting its backlog.
Outlook remains positive driven by defense budget tailwinds and strong contract wins, but valuation multiples like a P/E of 23.9 suggest limited upside from current levels. Risks include execution on large contracts and macroeconomic pressures on government spending.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
